ANXA1

Across TCGA pan-cancer cohorts, ANXA1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ANXA1 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ANXA1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANXA1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

GBM, UCEC, and LUAD are the cancer types where ANXA1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.619	0.868	<.001	15	view →
UCEC	OS	Median	II,III,IV	1.000	0.638	.014	12	view →
LUAD	DFS	Tertile	III,IV	0.302	0.838	.025	7	view →
HNSC	OS	Tertile	All	1.000	0.416	.040	6	view →
PDAC	OS	Median	All	0.714	0.927	.015	5	view →
LSCC	DFS	Median	II,III,IV	0.874	0.679	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ANXA1–GBM (DFS)

Open the GBM breakdown →